Sign In to Request a Protocol
Sign In to Request a Protocol

Thymosin Alpha-1 (5 mg Vial)

  • Table of Contents

Thymosin Alpha-1 Dosage Chart

Thymosin Alpha-1 is dosed at 300 mcg–500 mcg daily via subcutaneous injection in educational protocols. A 5 mg vial reconstituted with bacteriostatic water yields about 1.67 mg/mL. This information is for research and educational use only.

  • Reconstitute: Add 3.0 mL bacteriostatic water → ~1.67 mg/mL concentration.
  • Typical daily range: 300–500 mcg once daily (gradual titration).
  • Easy measuring: At 1.67 mg/mL, 1 unit = 0.01 mL ≈ 16.7 mcg on a U‑100 insulin syringe.
  • Storage: Lyophilized: refrigerate at 2–8 °C (35.6–46.4 °F) or freeze at −20 °C (−4 °F); after reconstitution, refrigerate and use within 7 days.

Thymosin Alpha-1 (Tα1) is a 28–amino acid peptide originally isolated from the thymus gland, recognized for its broad immunomodulatory properties. It has been investigated as an immune enhancer in chronic viral infections (hepatitis B/C, HIV/AIDS) and critical illness (sepsis, COVID-19). This educational protocol presents a once‑daily subcutaneous approach using a practical dilution for clear insulin‑syringe measurements.

Research context: For evidence on mechanisms, human and preclinical research, limitations, and safety.

  • Dosing & Reconstitution Guide

Educational guide for reconstitution and daily dosing

Standard / Gradual Approach (3 mL = ~1.67 mg/mL)

Route: Subcutaneous injection | Frequency: Once daily

WeekDaily Dose (mcg)Units (per injection) (mL)
Week 1300 mcg (0.3 mg)18 units (0.18 mL)
Weeks 2–8500 mcg (0.5 mg)30 units (0.30 mL)

Frequency: Inject once daily subcutaneously. This 8‑week protocol begins at 300 mcg to assess tolerance, then increases to a maintenance dose of 500 mcg daily from Week 2 onward. The 500 mcg daily dose yields ~3.5 mg/week, consistent with clinical dosing ranges. Treatment durations of 8–16 weeks are commonly reported in literature.

Reconstitution Steps

  • 1 . Draw 3.0 mL bacteriostatic water with a sterile syringe.
  • 2 . Inject slowly down the vial wall; avoid foaming or direct stream onto the powder.
  • 3 . Gently swirl or roll until fully dissolved (do not shake).
  • 4 . Label with reconstitution date and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.

Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

  • Product Details
  • Peptide Vials (Thymosin Alpha-1, 5 mg each):
  • 8 weeks: 4 vials
  • 12 weeks: 9 vials
  • 16 weeks: 12 vials
  • Insulin Syringes (U-100):
  • Per week: 7 syringes (1/day)
  • 8 weeks: 56 syringes
  • 12 weeks: 84 syringes
  • 16 weeks: 112 syringes
  • Bacteriostatic Water (10 mL bottles): Use 3.0 mL per vial for reconstitution.
  • 8 weeks (6 vials): 18 mL → 2 × 10 mL bottles
  • 12 weeks (9 vials): 27 mL → 3 × 10 mL bottle
  • 16 weeks (12 vials): 36 mL → 4 × 10 mL bottle
  • Alcohol Swabs: One for the vial stopper + one for the injection site each day.
  • Per week: 14 swabs (2/day)
  • 8 weeks: 112 swabs → recommend 2 × 100-count boxes
  • 12 weeks: 168 swabs → recommend 2 × 100-count box
  • 16 weeks: 224 swabs → recommend 3 × 100-count box
  • Protocol Overview

Concise summary of the once-daily regimen.

  • Goal: Support immune modulation and enhance host defense mechanisms.
  • Schedule: Daily subcutaneous injections for 8–12 weeks (extend to 16 weeks if desired).
  • Dose Range: 300–500 mcg daily with gradual titration.
  • Reconstitution: 3.0 mL per 5 mg vial (~1.67 mg/mL) for accurate unit measurements.
  • Storage: Lyophilized refrigerated or frozen; reconstituted refrigerated; use within 7 days.
  • Dosing Protocol

Suggested daily titration approach.

  • Start: 300 mcg daily for Week 1 to assess tolerance.
  • Target: 500 mcg daily from Week 2 onward.
  • Frequency: Once per day (subcutaneous).
  • Cycle Length: 8–12 weeks; optional extension to 16 weeks.
  • Timing: Any consistent time; rotate injection sites.
  • Storage Instructions

Proper storage preserves peptide quality.

  • Lyophilized: Store at 2–8 °C (35.6–46.4 °F) for short-term or −20 °C (−4 °F) for long-term; minimize moisture exposure.
  • Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within 7 days when using bacteriostatic water; avoid freeze–thaw.
  • Allow vials to reach room temperature before opening to reduce condensation uptake.
  • Important Notes

Practical considerations for consistency and safety.

  • Use new sterile insulin syringes; dispose in a sharps container.
  • Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation.
  • Inject slowly; wait a few seconds before withdrawing the needle.
  • Document daily dose and site rotation to maintain consistency.
  • Inspect solution before each use—do not use if cloudy or discolored.
  • How This Works

Thymosin Alpha-1 is a naturally occurring thymic peptide that modulates immune function through multiple pathways. It enhances the maturation and differentiation of T‑cells, augments dendritic cell function, and promotes the production of key cytokines including interferon‑α and interleukin‑2. Clinical studies have demonstrated Tα1’s ability to enhance immune responses in immunocompromised individuals, including those with chronic hepatitis B and C infections. Meta-analyses have also shown benefit in reducing mortality in moderate-to-critical COVID-19 patients.

  • Potential Benefits & Side Effects

Observations from preclinical and clinical literature.

  • Supports enhanced T‑cell function and overall immune competence.
  • Demonstrates an excellent safety profile; doses up to 1.6 mg twice weekly for 6–12 months have been well-tolerated.
  • Even at experimental doses up to 16 mg SC over 12 months, no significant Tα1‑specific toxicity has been observed.
  • Most common adverse effect is mild injection‑site irritation (redness or discomfort).
  • Lifestyle Factors

Complementary strategies for best outcomes.

  • Maintain adequate sleep and stress management to support immune function.
  • Consume a nutrient‑dense diet rich in vitamins C, D, and zinc.
  • Engage in moderate physical activity to complement immune optimization.
  • Avoid excessive alcohol and smoking, which impair immune responses.
  • Injection Technique

General subcutaneous guidance from clinical best‑practice resources

  • Clean the vial stopper and skin with alcohol; allow to dry.
  • Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue.
  • Do not aspirate for subcutaneous injections; inject slowly and steadily.
  • Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy.
  • Important Note

This content is for educational purposes only and is not medical advice.

  • References

Explore related research dosage protocols and background reading for BPC-157 + TB-500.

World Journal of Virology

— Dominari et al. (2020): Comprehensive review of Thymosin Alpha-1 mechanisms, dosing (0.8–6.4 mg SC), and clinical applications
More Info

Molecules (MDPI)

— Tao et al. (2023): Thymosin Alpha-1 in viral diseases—mechanisms and therapeutic applications in HBV, HCV, and HIV
More Info

Inflammopharmacology

— Soeroto et al. (2023): Meta-analysis of Tα1 in COVID-19; significant mortality reduction in moderate-to-critical patients
More Info

Expert Opinion on Biological Therapy

— Thymalfasin (Zadaxin) clinical overview: 1.6 mg SC twice weekly for hepatitis B treatment

More Info

Annals of the New York Academy of Sciences

— Thymosin Alpha-1: biological activities, clinical applications, and pharmacokinetics review
More Info

Clinical Immunology

— Mechanisms of thymosin alpha-1 immunomodulation: T-cell maturation and cytokine production
More Info

FDA Peptide Advisory Committee (2024)

— Safety data: Tα1 doses up to 16 mg SC for 12 months showed no significant toxicity

More Info

Hospital Pharmacy

— Jordan et al. (2021): Small-volume injection accuracy; recommends ≥20% syringe capacity for precision
More Info

CDC

— Vaccine administration: subcutaneous route (angle/site; no aspiration required)
More Info

Johns Hopkins Arthritis Center

— How to give a subcutaneous injection: site selection, rotation, and technique
More Info

NCBI Bookshelf

— Best practices for injection: asepsis, preparation, site rotation, and administration
More Info